Bastiaan Sallevelt

79 Evaluation of clarity of the STOPP/START criteria - SI Table SI1.1. Continued. STOPP Action Clarity rating Condition Clarity rating Explanation Clarity rating B5 Amiodarone 100% as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias 33% (higher risk of side-effects than beta-blockers, digoxin, verapamil or diltiazem) 83% B6 Loop diuretic 67% as first-line treatment for hypertension 33% (lack of outcome data for this indication; safer, more effective alternatives available). 33% B7 Loop diuretic 67% for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure 58% (leg elevation and /or compression hosiery usually more appropriate) 75% B8 Thiazide diuretic 67% with current significant hypokalaemia (i.e. serum K+ < 3.0 mmol/l), hyponatraemia (i.e. serum Na+ < 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium > 2.65 mmol/l) or with a history of gout 75% (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic). 83% B9 Loop diuretic 67% for treatment of hypertension with concurrent urinary incontinence 67% (may exacerbate incontinence). 58% 2